Healthcare / BiotechnologyShanghai
$24.05
-0.74 (-2.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-468.6M · quality 47.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-33.8%
↓Gross Margin
93.0%
↑Debt/Equity
0.67
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
+55.8%
FCF CAGR
—
FCF margin
-183.5%
FCF / Net income
0.79x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $230.7M · net income $-535.6M · FCF $-423.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $230.7M | $230.7M | $30.1M | $1.2M | $475240.96 | $39.2M |
| Net Income | $-535.6M | $-535.6M | $-797.3M | $-801.3M | $-576.4M | $-322.1M |
| EBITDA | $-433.4M | $-433.4M | $-698.7M | $-707.2M | $-493.7M | $-249.0M |
| EPS | -1.46 | -1.46 | -2.17 | -2.50 | -2.10 | -1.17 |
| Gross Margin | 93.0% | 93.0% | 82.4% | 38.9% | -11.4% | 50.5% |
| Operating Margin | -236.5% | -236.5% | -2777.6% | -64926.9% | -115642.5% | -749.7% |
| Net Margin | -232.2% | -232.2% | -2649.2% | -66142.6% | -121278.6% | -822.0% |
| Balance Sheet | ||||||
| Debt/Equity | 0.67 | 0.67 | 0.39 | 0.23 | 27.23 | 1.85 |
| Current Ratio | 4.78 | 4.78 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-423.3M | $-423.3M | $-620.8M | $-468.6M | $-323.8M | $-350.5M |
| Returns | ||||||
| ROE | -33.8% | -33.8% | -37.5% | -28.8% | -1981.9% | -103.3% |
| Valuation | ||||||
| P/B | 5.57 | 5.57 | 4.46 | 4.21 | — | — |
| Growth & Yield | ||||||
| Revenue Growth | 666.7% | 666.7% | 2384.1% | 154.9% | — | — |
| EPS Growth | 32.7% | 32.7% | 13.2% | -19.0% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-15.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.17 → -1.46
Residual
-15.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.